{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:57:21Z","timestamp":1795193841409,"version":"4.10.3"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      An evidence gap still exists regarding the efficacy and safety of tegoprazan in patients with erosive esophagitis (EE) in China. This study aimed to verify the efficacy and safety of tegoprazan\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . esomeprazole in patients with EE in China.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This study was a multicenter, randomized, double-blind, parallel, active-controlled, non-inferiority phase III trial of patients with EE randomized 1:1 to tegoprazan 50\u00a0mg\/day\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . esomeprazole 40\u00a0mg\/day. This study was conducted in 32\u00a0sites between October 24, 2018 and October 18, 2019. The primary endpoint was the cumulative endoscopic healing rate at week 8. The secondary endpoint included endoscopic healing rate at week 4, changes in the reflux disease questionnaire (RDQ) and gastroesophageal reflux disease health-related quality of life (GERD-HRQL) scores, and symptom improvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 261 patients were randomized: 132 to the tegoprazan group and 129 to the esomeprazole group. The cumulative endoscopic healing rate at 8\u00a0weeks in the tegoprazan group was non-inferior to that of the esomeprazole group (91.1%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 92.8%, difference: \u22121.7%, 95% confidence interval [CI]: \u22128.5%, 5.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.008). There were no statistically significant differences in the changes in RDQ (total, severity, and frequency) and GERD-HRQL scores between the two groups (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&gt;0.05). The percentages of days without symptoms, including daytime and nighttime symptoms based on patients\u2019 diaries, were similar between the two groups (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&gt;0.05). In the tegoprazan and esomeprazole groups, 71.5% (93\/130) and 61.7% (79\/128) of the participants reported adverse events (AEs), 2.3% and 0 experienced serious AEs, while 70.0% and 60.2% had treatment-emergent AEs, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Tegoprazan 50\u00a0mg\/day demonstrated non-inferior efficacy in healing EE, symptom improvement, and quality of life, and it has similar tolerability compared with esomeprazole 40\u00a0mg\/day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT03615677.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003276","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T10:07:08Z","timestamp":1730282828000},"page":"2464-2471","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase \u2162 trial"],"prefix":"10.1097","volume":"138","author":[{"given":"Huiyun","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiao","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pingxiang People\u2019s Hospital, Pingxiang, Jiangxi 337055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Lianyungang, Lianyungang, Jiangsu 222061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Wuxi People\u2019s Hospital, Wuxi, Jiangsu 214023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai East Hospital, Shanghai 200120, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lungen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai First People\u2019s Hospital, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Huashan Hospital Affiliated to Fudan University, Shanghai 200000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Yueyang, Yueyang, Hunan 414000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Changzhou, Changzhou, Jiangsu 213003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yangzhou First People\u2019s Hospital, Yangzhou, Jiangsu 225012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deliang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Huai\u2019an First People\u2019s Hospital, Nanjing Medical University, Huai\u2019an, Jiangsu 223300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"R1-20260407","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.pop.2017.07.001","article-title":"Gastroesophageal reflux disease","volume":"44","author":"Kellerman","year":"2017","journal-title":"Prim Care"},{"key":"R2-20260407","doi-asserted-by":"crossref","DOI":"10.7326\/L15-5181","article-title":"In the clinic. Gastroesophageal reflux disease","volume":"163","author":"Harnik","year":"2015","journal-title":"Ann Intern Med"},{"key":"R3-20260407","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R4-20260407","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","article-title":"Presentation and epidemiology of gastroesophageal reflux disease","volume":"154","author":"Richter","year":"2018","journal-title":"Gastroenterology"},{"key":"R5-20260407","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis","volume":"67","author":"Eusebi","year":"2018","journal-title":"Gut"},{"key":"R6-20260407","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci Rep"},{"key":"R7-20260407","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2468-1253(20)30007-8","article-title":"The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Kamangar","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R8-20260407","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-021-00287-w","article-title":"Gastro-oesophageal reflux disease","volume":"7","author":"Fass","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R9-20260407","article-title":"Advances in the diagnosis and management of gastroesophageal reflux disease","volume":"371","author":"Katzka","year":"2020","journal-title":"BMJ"},{"key":"R10-20260407","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"R11-20260407","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.gastro.2017.07.049","article-title":"Management of gastroesophageal reflux disease","volume":"154","author":"Gyawali","year":"2018","journal-title":"Gastroenterology"},{"key":"R12-20260407","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1586\/17474124.2016.1110017","article-title":"Diagnosis and treatment of small intestinal bacterial overgrowth","volume":"10","author":"Ponziani","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R13-20260407","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11894-015-0482-9","article-title":"How to test and treat small intestinal bacterial overgrowth: An evidence-based approach","volume":"18","author":"Rezaie","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"R14-20260407","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","article-title":"Meta-analysis: Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth","volume":"53","author":"Su","year":"2018","journal-title":"J Gastroenterol"},{"key":"R15-20260407","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"R16-20260407","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"R17-20260407","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers \u2013 are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"R18-20260407","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.15865","article-title":"Randomised clinical trial: Tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer","volume":"52","author":"Cho","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-20260407","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/apt.16477","article-title":"Randomised clinical trial: Comparison of tegoprazan and placebo in non-erosive reflux disease","volume":"54","author":"Kim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20260407","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: Tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20260407","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2212-0971(13)70046-3","article-title":"The Los Angeles classification of gastroesophageal reflux disease","volume":"1","author":"Sami","year":"2013","journal-title":"Video J Encycl of GI Endoscopy"},{"key":"R22-20260407","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2036.2010.04516.x","article-title":"Randomised clinical trial: A novel rabeprazole extended release 50\u00a0mg formulation vs. esomeprazole 40\u00a0mg in healing of moderate-to-severe erosive oesophagitis \u2013 the results of two double-blind studies","volume":"33","author":"Laine","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-20260407","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R24-20260407","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40\u00a0mg) compared with lansoprazole (30\u00a0mg) in the treatment of erosive esophagitis","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R25-20260407","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","article-title":"A randomized comparative study of esomeprazole 40\u00a0mg versus pantoprazole 40\u00a0mg for healing erosive oesophagitis: The EXPO study","volume":"21","author":"Labenz","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-20260407","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"R27-20260407","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/apt.17255","article-title":"Randomised clinical trial: Comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis","volume":"57","author":"Cho","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20260407","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5056\/jnm22104","article-title":"Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: A multicenter double-blind randomized controlled trial","volume":"29","author":"Kim","year":"2023","journal-title":"J Neurogastroenterol Motil"},{"key":"R29-20260407","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jgh.16471","article-title":"The efficacy and safety of fexuprazan in treating erosive esophagitis: A phase III, randomized, double-blind, multicenter study","volume":"39","author":"Zhuang","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"R30-20260407","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: A phase III, randomised, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R31-20260407","doi-asserted-by":"crossref","first-page":"17562848221122623","DOI":"10.1177\/17562848221122623","article-title":"The role of vonoprazan in patients with erosive esophagitis","volume":"15","author":"Zhang","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"R32-20260407","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/apt.15062","article-title":"Randomised clinical trial: Vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis","volume":"49","author":"Oshima","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-20260407","first-page":"148","article-title":"Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors","volume":"8","author":"Mizuno","year":"2018","journal-title":"Biomed Rep"},{"key":"R34-20260407","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3748\/wjg.v10.i12.1750","article-title":"Effects of Helicobacter pylori infection on gastric emptying rate in patients with non-ulcer dyspepsia","volume":"10","author":"Leontiadis","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R35-20260407","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.3748\/wjg.v22.i18.4585","article-title":"Changes in patients\u2019 symptoms and gastric emptying after Helicobacter pylori treatment","volume":"22","author":"Zhang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R37-20260407","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02942830","article-title":"Helicobacter pylori and gastro-oesophageal reflux disease\u2013a prospective study","volume":"163","author":"O\u2019Connor","year":"1994","journal-title":"Ir J Med Sci"},{"key":"R38-20260407","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1590\/0102-6720201600030002","article-title":"Relationship between esophagitis grades and Helicobacter pylori","volume":"29","author":"Ribeiro","year":"2016","journal-title":"Arq Bras Cir Dig"},{"key":"R39-20260407","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1111\/j.1572-0241.1999.03378.x","article-title":"Helicobacter pylori and omeprazole therapy in GERD","volume":"94","author":"Kuipers","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R40-20260407","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4293\/108680812X13427982376860","article-title":"The effect of Helicobacter pylori on gastroesophageal reflux disease","volume":"16","author":"Polat","year":"2012","journal-title":"JSLS"},{"key":"R41-20260407","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9270(00)00775-9","article-title":"The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection","volume":"95","author":"Berc\u00edk","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R42-20260407","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1053\/gast.1996.v110.pm8608881","article-title":"Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer","volume":"110","author":"Labenz","year":"1996","journal-title":"Gastroenterology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:01:01Z","timestamp":1775592061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":41,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003276","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"2024-03-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}